Evidence map›Paper›PMID 31809899›Full record

ArticleClinical immunology (Orlando, Fla.)2020

IL-6 is present in beta and alpha cells in human pancreatic islets: Expression is reduced in subjects with type 1 diabetes.

Sakthi Rajendran, Florence Anquetil, Estefania Quesada-Masachs, Madeleine Graef, Nathaly Gonzalez, Sara McArdle, Tiffany Chu, Lars Krogvold, Knut Dahl-Jørgensen, Matthias von Herrath

Open access · greenAbstract read
In one paragraph

Article in Clinical immunology (Orlando, Fla.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Role of mitochondrial DNA in diabetes Mellitus Type I and Type II.Saudi journal of biological sciences · 2022
    Review
  17. Article
  18. Article
  19. Article
  20. The Role of Mitochondrial Mutations and Chronic Inflammation in Diabetes.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Sakthi RajendranLa Jolla Institute for Immunology, La Jolla, CA, United States of America.
Florence AnquetilLa Jolla Institute for Immunology, La Jolla, CA, United States of America.
Estefania Quesada-MasachsLa Jolla Institute for Immunology, La Jolla, CA, United States of America.
Madeleine GraefLa Jolla Institute for Immunology, La Jolla, CA, United States of America.
Nathaly GonzalezLa Jolla Institute for Immunology, La Jolla, CA, United States of America.
Sara McArdleLa Jolla Institute for Immunology, La Jolla, CA, United States of America.
Tiffany ChuLa Jolla Institute for Immunology, La Jolla, CA, United States of America.
Lars KrogvoldDivision of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway; Faculty of Odontology, University of Oslo, Oslo, Norway.
Knut Dahl-JørgensenDivision of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway.
Matthias von HerrathLa Jolla Institute for Immunology, La Jolla, CA, United States of America. Electronic address: matthias@lji.org.
La Jolla Institute for Immunology · USUniversity of Oslo · NO

Funding

Specificity, Phenotype and Function of Pancreatic CD8 T Cells in Human Type 1 DiabetesR01AI092453 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Estefania Quesada Masachs · 2011 to 2026
$5.7M
Integrated Functional Histopathology of the Diabetic Human PancreasR01AI134971 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI HOMANN, DIRK, VON HERRATH, MATTHIAS G. · 2018 to 2022
$3.5M
NIAID NIH HHS R01 AI092453NIAID NIH HHS R01 AI134971
6 · The paper itself

Abstract

IL-6 is a pro-inflammatory cytokine upregulated in some autoimmune diseases. The role of IL-6 in the development of type 1 diabetes (T1D) is unclear. Clinical studies are investigating whether tocilizumab (anti-IL-6 receptor) can help preserve beta cell function in patients recently diagnosed with T1D. However, in some rodent models and isolated human islets, IL-6 has been found to have a protective role for beta cells by reducing oxidative stress. Hence, we systematically investigated local tissue expression of IL-6 in human pancreas from non-diabetic, auto-antibody positive donors and donors with T1D and T2D. IL-6 was constitutively expressed by beta and alpha cells regardless of the disease state. However, expression of IL-6 was highly reduced in insulin-deficient islets of donors with T1D, and the expression was then mostly restricted to alpha cells. Our findings suggest that the implication of IL-6 in T1D pathogenesis might be more complex than previously assumed.

Indexed as

AdolescentAdultAgedDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2FemaleGlucagon-Secreting CellsHumansInsulin-Secreting CellsInterleukin-6MaleMiddle AgedYoung AdultIL6 protein, humanInterleukin-6

Identifiers

PMID31809899
PMCPMC6961707
OpenAlexW2992454425

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.